Incidence of second hip fracture and compliant use of bisphosphonate
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Y. -K. | - |
dc.contributor.author | Ha, Y. -C. | - |
dc.contributor.author | Yoon, B. -H. | - |
dc.contributor.author | Koo, K. -H. | - |
dc.date.available | 2019-03-09T01:41:29Z | - |
dc.date.issued | 2013-07 | - |
dc.identifier.issn | 0937-941X | - |
dc.identifier.issn | 1433-2965 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/14492 | - |
dc.description.abstract | We determined the incidence of second hip fracture and evaluated whether compliant users of bisphosphonate had a lower incidence of second hip fracture after prior hip fracture. Bisphosphonate has been used to prevent osteoporotic fracture and is recommended for the secondary prevention after hip fracture. However, little is known regarding secondary prevention after first hip fracture. Our purpose was to determine the incidence of second hip fracture and to evaluate whether compliant use of bisphosphonate can reduce the risk of second hip fracture. Eight hundred twenty-six patients who sustained the first hip fracture from May 2003 to October 2011 were retrospectively evaluated. The incidence of second hip fracture was compared between compliant users of bisphosphonate and nonusers. Seventy-one (8.6 %) patients suffered a second hip fracture at mean 30.0 months (SD 24.6, range 1 to 90 months) after the initial hip fracture. The cumulative incidence of second hip fracture was 5.1 % (42/826) at 2 years and 8.6 % (71/826) at 8 years. The incidence of second hip fracture was 4.2 % (12/283) in compliant users and 10.9 % (59/543) in nonusers (p = 0.001). Compliant use of bisphosphonate is effective in the prevention of second hip fractures. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | SPRINGER LONDON LTD | - |
dc.title | Incidence of second hip fracture and compliant use of bisphosphonate | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s00198-012-2250-0 | - |
dc.identifier.bibliographicCitation | OSTEOPOROSIS INTERNATIONAL, v.24, no.7, pp 2099 - 2104 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000320283300017 | - |
dc.identifier.scopusid | 2-s2.0-84879228998 | - |
dc.citation.endPage | 2104 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 2099 | - |
dc.citation.title | OSTEOPOROSIS INTERNATIONAL | - |
dc.citation.volume | 24 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | Bisphosphonate | - |
dc.subject.keywordAuthor | Compliance | - |
dc.subject.keywordAuthor | Hip fracture | - |
dc.subject.keywordAuthor | Second hip fracture | - |
dc.subject.keywordPlus | OSTEOPOROTIC FRACTURES | - |
dc.subject.keywordPlus | RISK-FACTORS | - |
dc.subject.keywordPlus | POSTMENOPAUSAL WOMEN | - |
dc.subject.keywordPlus | FUNCTIONAL RECOVERY | - |
dc.subject.keywordPlus | ELDERLY-PATIENTS | - |
dc.subject.keywordPlus | MEN | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.subject.keywordPlus | EPIDEMIOLOGY | - |
dc.subject.keywordPlus | PERSISTENCE | - |
dc.subject.keywordPlus | ALENDRONATE | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.